-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

Benzinga·10/28/2026 14:01:18
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.